Du är här



Carlsbad, California, April 24, 2014
/Marketwired/ - Aurora Spine Corporation (TSXV:ASG) announced today that it
has received U.S. Food and Drug Administration (FDA) 510(k) clearance for
additional sizes of the company's sterile-packed ZIP ULTRA(TM) Minimally
Invasive Interspinous Fusion System and clearance for the company's new
sterile-packed ZIP(TM) MIS system.

The additional ZIP ULTRA sizes, 35mm and 40mm, expand the company's growing
portfolio to better conform to patient anatomy. This is another step in
Aurora Spine's effort to provide the highest quality products to improve the
techniques and outcomes of spine surgery and help patients resume their
normal routines as quickly as possible. The additional sizes have already
been used in surgeries in Europe under the company's CE Mark approval.

The ZIP(TM) features non-articulating bone anchors, Aurora Spine's patent
pending one-step locking mechanism with no set screw and a large graft space
designed for biologic material. With the receipt of the FDA clearance for
the ZIP in all three sizes (35mm, 40mm and 45mm), the new ZIP line will be
available at the end of the third quarter of 2014.

"The receipt of these additional FDA 510(k) clearances for our ZIP Ultra(TM)
and ZIP(TM) MIS Interspinous Fusion System is another key milestone for
Aurora Spine and allows us to expand our spinal product portfolio in the U.S.
and key global markets. This achievement is a testament to the ongoing
dedication and perseverance of our team," said Trent J. Northcutt, President
and Chief Executive Officer of Aurora Spine. "I am delighted we have obtained
additional FDA clearances, especially given the overwhelming response for the
ZIP devices. The success of our screw-less spine procedure is a testament to
our laser focus on disruptive technology and our commitment to 'Simplifying
the Complex'."

About Aurora Spine

Aurora Spine is an early stage company focused on bringing new solutions to
the spinal implant market through a series of innovative, minimally invasive,
regenerative spinal implant technologies.

Forward-Looking Statements

This news release contains forward-looking information that involves
substantial known and unknown risks and uncertainties, most of which are
beyond the control of Aurora Spine, including, without limitation, those
listed under "Risk Factors
" and "Cautionary Statement Regarding Forward-Looking Information
" in Aurora Spine's final prospectus (collectively, "forward-looking
information"). Forward-looking information in this news release includes
information concerning the proposed marketing and commercialization of Aurora
Spine's products. Aurora Spine cautions investors of its securities about
important factors that could cause Aurora Spine's actual results to differ
materially from those projected in any forward-looking statements included in
this news release. Any statements that express, or involve discussions as to,
expectations, beliefs, plans, objectives, assumptions or future events or
performance are not historical facts and may be forward-looking and may
involve estimates, assumptions and uncertainties which could cause actual
results or outcomes to differ unilaterally from those expressed in such
forward-looking statements. No assurance can be given that the expectations
set out herein will prove to be correct and, accordingly, prospective
investors should not place undue reliance on these forward looking
statements. These statements speak only as of the date of this press release
and Aurora Spine does not assume any obligation to update or revise them to
reflect new events or circumstances.

For more information, please contact

Aurora Spine Corporation

Trent Northcutt
President and Chief Executive Officer
(760) 424-2004

Eric Fronk
Chief Financial Officer
(760) 424-2004

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Aurora Spine Corporation via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.